News
today announced Cohort 3 data from the ongoing Phase 2 trial of SLS009 (tambiciclib), a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML). “The remarkable ...
today announced Cohort 3 data from the ongoing Phase 2 trial of SLS009 (tambiciclib), a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML). “The remarkable ...
MDX Research Center for Element Strategy, Institute of Integrated Research, Institute of Science Tokyo, 4259 Nagatsuta, Midori, Yokohama 226-8501, Japan MDX Research Center for Element Strategy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback